Journal of Cardiac Failure
IF
5.71
Papers
14.9k
Papers 10,000
1 page of 1,000 pages (10k results)
Newest
#1Khatia Gabisonia (Sant'Anna School of Advanced Studies)H-Index: 3
#2Gia Burjanadze (Sant'Anna School of Advanced Studies)
Last. Takhar Kasumov (NEOMED: Northeast Ohio Medical University)H-Index: 32
view all 13 authors...
Protein pool turnover is a critically important cellular homeostatic component, yet it has been little explored in the context of heart failure (HF) pathophysiology. We employed in vivo 2H labeling/ proteome dynamics for non-biased discovery of turnover alterations involving functionally linked cardiac and plasma proteins in canine tachypacing-induced HF, an established preclinical model of dilated cardiomyopathy. Compared to control, dogs with congestive HF displayed bidirectional turnover chan...
Source
#1Muthiah Vaduganathan (BWH: Brigham and Women's Hospital)H-Index: 58
#2Stephen J. Greene (Duke University)H-Index: 40
Last. Gregg C. Fonarow (UCLA: University of California, Los Angeles)H-Index: 180
view all 18 authors...
Background null The sodium-glucose cotransporter-2 (SGLT-2) inhibitors form the latest pillar in the management of heart failure with reduced ejection fraction (HFrEF) and appear effective across a range of patient profiles. There is increasing interest around initiation of SGLT-2 inhibitor during hospitalization, yet little is known about the putative benefits of this implementation strategy. null Methods null We evaluated Medicare beneficiaries with HFrEF (≤40%) hospitalized at 228 sites in th...
Source
#1Ramesh WariarH-Index: 2
#2Gezheng WenH-Index: 5
Last. John P. Boehmer (PSU: Pennsylvania State University)H-Index: 45
view all 5 authors...
Background null Although claims data provide a large and efficient source of clinical events, validation is needed prior to use in heart failure (HF) diagnostic development. null Methods and results null MultiSENSE study data, used to create the HeartLogic HF diagnostic, were linked with fee-for-service (FFS) Medicare claims. Events were matched by patient ID and date, and agreement calculated between claims primary HF diagnosis codes and study event adjudication. HF events (HFEs) were defined a...
Source
#1Kimberly N. Hong (UCSD: University of California, San Diego)H-Index: 6
#2Carol E. Battikha (UCSD: University of California, San Diego)
Last. Eric Adler (UCSD: University of California, San Diego)H-Index: 27
view all 19 authors...
BACKGROUND Danon disease (DD) is a rare X-linked dominant cardioskeletal myopathy caused by mutations in the lysosome-associated membrane protein-2 (LAMP-2) gene that is usually lethal without cardiac transplantation. The purpose of this study is to characterize post-transplant outcomes in a large cohort of DD patients who underwent cardiac transplantation. METHODS Clinical phenotype and outcome data of patients with DD who underwent cardiac transplantation (N=38, 19 males and 19 females) were o...
Source
#1Matthew J. Singleton (Wake Forest University)H-Index: 4
#2M. Benjamin Nelson (Wake Forest University)H-Index: 5
Last. Michael D. Nelson (UTA: The University of Texas at Arlington)H-Index: 23
view all 9 authors...
ABSTRACT null null Background null : Heart failure with preserved ejection fraction (HFpEF) is the fastest growing form of HF and is associated with high morbidity and mortality. The primary chronic symptom in HFpEF is exercise intolerance, associated with reduced quality of life (QoL). Emerging evidence implicates left atrial (LA) dysfunction as an important pathophysiologic mechanism. Here we extend prior observations by relating LA dysfunction to peak oxygen uptake (peak VO2), physical functi...
Source
#1Mark N. Belkin (UC: University of Chicago)H-Index: 4
#2Francis J. Alenghat (UC: University of Chicago)H-Index: 14
Last. Jonathan Grinstein (UC: University of Chicago)H-Index: 9
view all 5 authors...
ABSTRACT null null Introduction null : The initial derivation of cardiac power output (CPO) included the difference between mean arterial pressure (MAP) and right atrial pressure (RAP) in the numerator, before multiplying by cardiac output (CO). We hypothesized that the inclusion of RAP (CPO-RAP) would enhance the prognostic performance of this parameter in those with elevated RAP. null null null Methods null : We obtained patient-level data from ESCAPE trial via the Biolincc database. Participa...
Source
#1Ioannis Mastoris (KU: University of Kansas)H-Index: 9
#2Harriette G.C. Van Spall (PHRI: Population Health Research Institute)H-Index: 18
Last. Andrew J. Sauer (KU: University of Kansas)H-Index: 13
view all 9 authors...
Cardiac implantable electronic devices (CIEDs), including implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy (CRT), are part of guideline- indicated treatment for a subset of patients with heart failure with reduced ejection fraction (HFrEF). Current technological advancements in CIEDs have allowed the detection of specific patient physiologic parameters used for forecasting clinical decompensation through algorithmic, multiparameter remote monitoring. Other rec...
Source
#1Saeed Juggan (Dartmouth College)
#2Praveen K. Ponnamreddy (DHMC: Dartmouth–Hitchcock Medical Center)
Last. Emily P. Zeitler (Dartmouth College)H-Index: 13
view all 6 authors...
Abstract null null Objective null : To perform meta-analyses comparing safety and effectiveness of cardiac resynchronization therapy (CRT) in older versus younger patients with heart failure with reduced ejection fraction (HFrEF). null null null Background null : Pivotal CRT trials enrolled patients with HFrEF significantly younger than the typical contemporary patient with HFrEF. Thus, risks and benefits in this older population with HFrEF are largely unknown. null null null Methods null : PubM...
Source
#1Nuccia MoriciH-Index: 20
#2Claudia MariniH-Index: 10
Last. Federico Pappalardo (UNIMIB: University of Milano-Bicocca)
view all 12 authors...
The Intra-aortic balloon pump (IABP) is widely implanted as temporary mechanical circulatory support for cardiogenic shock (CS). However, its use is declining following the results of the IABP-SHOCK II trial, which failed to show a clinical benefit of IABP in acute coronary syndrome (ACS) related CS. Acute-on-chronic heart failure has become an increasingly recognized, distinct etiology of CS (HF-CS). The pathophysiology of HF-CS differs from ACS-CS, as it typically represents the progression fr...
Source
#1Anna ApostoloH-Index: 24
#2Carlo Vignati (UNIMI: University of Milan)H-Index: 14
Last. Piergiuseppe Agostoni (UNIMI: University of Milan)H-Index: 65
view all 13 authors...
BACKGROUND In advanced heart failure (HF), Levosimendan increases peak oxygen uptake (peakVO2). We investigated whether peakVO2 increase is linked to cardiovascular, respiratory or muscular performance changes. METHODS AND RESULTS Twenty patients hospitalized for advanced HF underwent, before and shortly after Levosimendan infusion, two different cardiopulmonary exercise tests (CPET): a) a personalized ramp protocol with repeated arterial blood gas analysis and standard spirometry including alve...
Source
12345678910
Top fields of study
This website uses cookies.
We use cookies to improve your online experience. By continuing to use our website we assume you agree to the placement of these cookies.
To learn more, you can find in our Privacy Policy.